Financials
Financial year 2025
MEDIGENA from Hamois, company number BE0803437439, closed financial year 2025 with a result of € 14,379 after tax. For that financial year MEDIGENA recorded a gross margin of € 88,886 and equity of € 30,000. Compared with financial year 2024, the result moved from € 54,065 to € 14,379. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 9, 2026.
€ 30,000
▼ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 14,379
▼ 73% vs 2024
Profit after tax over the fiscal year.
€ 28,576
▼ 16% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 20,320 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 108,301
▼ 2% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 415,006
▼ 10% vs 2024
€ 45,770 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 15,742
▼ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 41,007 | € 120,045 | € 88,886 | ▼ 26% |
| Profit after taxes | € 14,376 | € 54,065 | € 14,379 | ▼ 73% |
| Equity | € 31,876 | € 35,940 | € 30,000 | ▼ 17% |
| Total debts | € 420,953 | € 533,250 | € 458,155 | ▼ 14% |
| Cash | € 65,407 | € 33,831 | € 28,576 | ▼ 16% |
| Retained profit | € 1,876 | € 5,940 | € 0 | ▼ 100% |
| Dividend | € 12,500 | € 50,000 | € 20,320 | ▼ 59% |
| Bank debt | € 396,670 | € 459,054 | € 415,006 | ▼ 10% |
| Balance sheet total | € 452,828 | € 569,190 | € 488,155 | ▼ 14% |
Key figures of MEDIGENA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIGENA?
What happened at MEDIGENA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 14,379 (▼ 73% vs 2024). filed late Source: NBB ↗
- New establishment in Hamois. KBO
- Start of the company according to the CBE. KBO
- SANDRA BALLARD became a director. NBB
- MG BALTHAZAR ET BALLARD SRL became a director. NBB
In short
From € 14,376 profit in 2023 to € 14,379 profit in 2025.
Paid € 680 in corporate taxes since 2023.
Best year ever: 2024, with € 54,065 profit.
Paid out € 82,820 in dividends to the owners in total.
Management
The stake of MG BALTHAZAR ET BALLARD comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MEDIGENABehind MEDIGENA are SANDRA BALLARD and MG BALTHAZAR ET BALLARD SRL. The shares are held by MG BALTHAZAR ET BALLARD (100%).
Directors
According to the 2025 annual accounts
since 2023
Director · represented by BALTHAZAR YOHAN
since 2023
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Chaussée de Namur, Natoye 73
5360 Hamois
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.437.439
- VAT number
- BE 0803.437.439
- Registered office
- Chaussée de Namur, Natoye 73, 5360 Hamois
- Names & denominations
- MEDIGENA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 June 2023
- Peppol
- Active · Active since 17 Nov 2025
- Activities · NACE
Activiteiten van medisch specialisten